Life Technologies Expands Range of Stem Cell Reprogramming Solutions

     Life Technologies Expands Range of Stem Cell Reprogramming Solutions

Epi5™ iPSC Reprogramming Vectors developed in collaboration with Nobel
Prize-winning research team for reprogramming technology

PR Newswire

CARLSBAD, Calif., June 17, 2013

CARLSBAD, Calif., June 17, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) today announced the launch of Epi5™ Episomal iPSC Reprogramming
Vectors, the world's first product to be fully commercialized based on
technology that won its developers a Nobel Prize in 2012 for the ability to
easily reprogram adult human cells into an early embryonic state.

Scientists use induced pluripotent stem cell (iPSC) technology to create iPSCs
from patient-derived adult somatic cells. The iPSCs can then be differentiated
into many cell types, such as neurons and hepatocytes, to be studied in the
lab. The ease-of-use and reprogramming efficiency of Epi5™ Episomal iPSC
Reprogramming Vectors helps accelerate the process for applications in basic
research and pre-clinical studies.

"You can give rise to iPSCs at a high efficiency rate by using the
Epi5™Episomal iPSC ReprogrammingKit," said Dr. Keisuke Okita, Lecturer,
Center for iPS Cell Research and Application, Kyoto University, who helped
developed the Nobel Prize-winning technology with Dr. Shinya Yamanaka."We are
delighted to see that Life Technologies is taking the lead to make it
available and we hope that many researchers will use it to advance research in
areas such as pathology, drug discovery and stem cell biology."

While other reprogramming vectors have been developed in Dr. Yamanaka's lab,
none has ever been commercially available. Epi5™ Episomal iPSC Reprogramming
Vectors is the result of a global, non-exclusive license agreement Life
Technologies signed last year with iPS Academia Japan for its iPSC patent
portfolio. The license expands Life's range of products and services and
underscores the company's commitment to provide the most innovative tools to
the iPSC community.

"The ability to easily generate iPS cells from patient-derived adultsomatic
cells allows researchers to study the genetics behind specific diseases," said
Chris Armstrong, Ph.D., General Manager and Vice President of Primary and Stem
Cell Systems at Life Technologies. "This is a crucial step toward development
of new potential treatments and one that we are committed to supporting with
leading technologies."

Epi5™ Episomal iPSC Reprogramming Vectors is For Research Use Only, not
intended for diagnostic purposes.

About Life Technologies
Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the information
contained in this press release, including, but not limited to, statements as
to industry trends and Life Technologies' plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results or events
to differ materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical fact are
forward-looking statements. When used, the words "believe," "plan," "intend,"
"anticipate," "target," "estimate," "expect" and the like, and/or future tense
or conditional constructions ("will," "may," "could," "should," etc.), or
similar expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ materially from
those in the forward-looking statements are detailed in filings made byLife
Technologies with the Securities and Exchange Commission.Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.


Life Technologies Contact
Mauricio Minotta

SOURCE Life Technologies Corporation

Press spacebar to pause and continue. Press esc to stop.